• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Alvotech

33.00 SEK+4.60 %15.7. klo 18.29
Less than 1K followers

ALVO SDB

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Compare
+4.60 %
-15.82 %
-4.62 %
-25.00 %
-28.94 %
-59.81 %
-
-
-66.43 %

Alvotech is a biotechnology company that focuses on the development and manufacture of biosimilar medicines. The company's pipeline consists of biosimilar candidates aimed at treating autoimmune diseases, eye diseases, osteoporosis and cancer. The company offers its products to patients all over the world. Alvotech was founded in 2013 and has its headquarters in Reykjavík.

Read more
Market cap
12.88B SEK
Turnover
178.18K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
20.8.
2026

Interim report Q2'26

12.11.
2026

Interim report Q3'26

11.3.
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release03.07.2026 klo 23.01

Transactions of Managers and Closely Associated Persons

Alvotech
Regulatory press release01.07.2026 klo 11.00

Alvotech further strengthens liquidity by securing term loan facility of $75 million

Alvotech
Regulatory press release23.06.2026 klo 01.47

Transactions of Managers and Closely Associated Persons

Alvotech

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release18.06.2026 klo 11.00

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement

Alvotech
Regulatory press release16.06.2026 klo 06.50

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

Alvotech
Regulatory press release15.06.2026 klo 23.01

Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

Alvotech
Regulatory press release10.06.2026 klo 23.30

Transactions of Managers and Closely Associated Persons

Alvotech
Regulatory press release08.06.2026 klo 11.00

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

Alvotech
Regulatory press release04.06.2026 klo 11.00

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

Alvotech
Regulatory press release03.06.2026 klo 23.30

Main Results of 2026 Annual and Extraordinary General Meeting

Alvotech
Regulatory press release02.06.2026 klo 23.30

Alvotech to present at upcoming investor conferences in June

Alvotech
Regulatory press release01.06.2026 klo 11.30

Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland

Alvotech
Regulatory press release11.05.2026 klo 11.30

Alvotech announces completion of FDA surveillance inspection at Reykjavik facility

Alvotech
Regulatory press release06.05.2026 klo 23.30

Alvotech Q1 2026 Financial Results

Alvotech
Regulatory press release30.04.2026 klo 23.30

Alvotech Announces a Change in its Executive Team

Alvotech
Regulatory press release24.04.2026 klo 15.30

Alvotech to Report Financial Results for the First Quarter of 2026

Alvotech
Regulatory press release31.03.2026 klo 02.57

Alvotech files Annual Report with the SEC

Alvotech
Regulatory press release31.03.2026 klo 02.55

Alvotech Publishes 2025 Annual Report

Alvotech
Regulatory press release19.03.2026 klo 00.15

Alvotech Q4 2025 and Full Year 2025 Financial Results

Alvotech
Regulatory press release04.03.2026 klo 10.00

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

Alvotech